• Earth Science Tech posted revenue of $35.7 million, up 8% year over year, as demand rose for compounded medications across its platforms.
• Net income available to common stockholders climbed 12% to $3.63 million, while gross margin narrowed 2 percentage points to 71%.
• Advertising and marketing expense more than doubled to $2.84 million, driven by expanded digital marketing on social media and search advertising.
• Operating cash flow fell to $1.94 million from the prior year, while net cash used in financing activities totaled $712,917 on stock repurchases.
• Management said current operating cash flow should cover operating and capital needs for the next 12 months, without additional dilutive financing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Earth Science Tech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-029160), on June 18, 2026, and is solely responsible for the information contained therein.